UBS Group AG CLGN β€” COLLPLANT BIOTECHNOLOGIES LT

Ownership history in UBS Group AG  Β·  15 quarters on record

AI Ownership Summary

UBS Group AG reported COLLPLANT BIOTECHNOLOGIES LT (CLGN) in 15 quarterly 13F filings from 2024 Q1 through 2026 Q1. The latest visible filing shows CLGN at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this CLGN ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was UBS Group AG's position in COLLPLANT BIOTECHNOLOGIES LT, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

CLGN was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2024 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

CLGN stock page UBS Group AG fund profile UBS Group AG full holdings
How UBS Group AG held CLGN β€” position size vs. price
% of Fund (quarterly)    CLGN price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
πŸ“‹ Quarterly Holdings History 6 quarters  β–Ύ
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 REDUCED β€” β€” β€” 95 -23,979 -99.6% 0.00% $51 2026-05-05 $0.40
2025 Q1 ADDED β€” β€” β€” 24,074 +1,866 +8.4% 0.00% $62K 2025-05-13 $1.55
2024 Q4 ADDED β€” β€” β€” 22,208 +10,261 +85.9% 0.00% $80K 2025-02-14 $3.60
2024 Q3 ADDED β€” β€” β€” 11,947 +4,805 +67.3% 0.00% $59K 2024-11-14 $4.25
2024 Q2 ADDED β€” β€” β€” 7,142 +2,362 +49.4% 0.00% $35K 2024-08-14 $4.49
2024 Q1 REDUCED 16.0% -6.5% βœ… 4,780 -910 -16.0% 0.00% $26K 2024-05-13 $6.57
9 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

🏒 Other funds also holding CLGN

As of 2026 Q1 β€” sorted by position size

VILLERE ST DENIS J & CO LLC 3Y 7Y 0.04% Legacy Wealth Managment, LLC/ID 0.01% PINNACLE ASSOCIATES LTD 3Y 7Y 0.0% FNY Investment Advisers, LLC 3Y 7Y 0.0% WATERS PARKERSON & CO., LLC 3Y 7Y 0.0% SBI Securities Co., Ltd. 0.0%

FAQ About UBS Group AG and CLGN

These are the practical questions this page is built to answer before you even open the full history table.

How long has UBS Group AG reported owning CLGN?

UBS Group AG reported CLGN across 6 quarterly 13F filings, from 2024 Q1 through 2026 Q1.

What was the largest reported CLGN position in UBS Group AG's portfolio?

The largest reported portfolio weight for CLGN was 0.00% in 2024 Q4.

What is the latest reported CLGN position on this page?

The most recent filing on this page is 2026 Q1, when UBS Group AG reported 95 shares, equal to 0.00% of portfolio, with an estimated market value of $51.

What does the chart on this CLGN ownership page compare?

The chart compares UBS Group AG's quarterly CLGN portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did UBS Group AG time their CLGN position?

Based on 13F filing dates vs. subsequent CLGN price moves, UBS Group AG correctly timed 4 out of 14 reported position changes (29%).

← Back to UBS Group AG Holdings